RxDoctor Payments Data

Wai-Kuen Lam, MD

Internal Medicine · Flushing, NYNPI 1700969920

Payments from drug & device makers

$1,892in general payments, 2019–2025

Across 17 payments — averaging $111.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$659
  • Amgen$356
  • AstraZeneca$267
  • E.r. Squibb & Sons, L.L.C.$247
  • Daiichi Sankyo Inc.$125
  • Merck$122
  • plus $118 from 1 others

What the payments were for

  • Food & beverage$1,87399%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie6$659
Amgen3$356
AstraZeneca(2 entities)3$267
E.r. Squibb & Sons, L.L.C.2$247
Daiichi Sankyo Inc.1$125
Merck1$122
GSK1$118

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,892 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$92,107
Medicare patients
142
Services billed
1,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol209$199,949
Diclofenac Epolamine255$196,720
JardianceEmpagliflozin192$168,232
JanuviaSitagliptin Phosphate138$122,763
VascepaIcosapent Ethyl184$92,966
JanumetSitagliptin Phos/Metformin Hcl119$91,386
SynjardyEmpagliflozin/Metformin Hcl62$49,128
ProliaDenosumab23$39,974
RybelsusSemaglutide37$38,775
RestasisCyclosporine55$38,232
TradjentaLinagliptin43$30,535
OzempicSemaglutide17$16,476
Tresiba Flextouch U-100Insulin Degludec19$12,309
NexlizetBempedoic Acid/Ezetimibe14$11,784
DapagliflozinDapagliflozin Propanediol13$10,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$122$214,150257 claims
AstraZenecaFarxiga, Symbicort$267$206,030233 claims
AbbVieRestasis, Namzaric, Synthroid$659$49,002104 claims
AmgenProlia$356$39,97423 claims
GSKTrelegy Ellipta$118$8,58113 claims
Daiichi Sankyo Inc.Benicar$125$5,94820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →